- Under the deal, Agenus will receive $150 million upon closing, including a $120 million upfront cash payment and $30 million in equities. Agenus will also receive up to about $1.7 billion in potential future fees and milestones.
Dec 20 (Reuters) - Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.
Agenus will get an upfront cash payment of $120 million and a $30 million equity investment, and will also be eligible to receive about $1.7 billion in potential future fees and milestones, the companies said in a statement on Thursday.
No comments:
Post a Comment